Cohance Lifesciences saw its Q1 FY27 EBITDA drop 93.2% to ₹9.2 crore as revenue fell 23.1% due to regulatory hurdles and subsidiary losses. New Group CEO Umang Vohra expects the June quarter to mark the bottom, with plans for a recovery in the second half. Investors are currently tracking the company’s ability to resolve USFDA observations and improve operational efficiency.
Cohance Lifesciences faced a difficult first quarter for fiscal year 2027, reporting a significant decline in financial performance. The company’s consolidated revenue for the period fell by 23.1% year-on-year to ₹422.3 crore. Even more stark was the decline in operating profitability, with adjusted EBITDA falling by 93.2% to ₹9.2 crore. This weak performance highlights the challenges the company is facing after its rapid expansion through various acquisitions.
Operational and Regulatory Challenges
The drop in profitability was driven by multiple factors. The company’s US-based subsidiary, NJ Bio, reported an EBITDA loss of ₹32.8 crore during the quarter, putting pressure on the overall consolidated financials. Beyond the subsidiary, the company is dealing with external pressures, including weak demand in the agrochemical segment and ongoing inventory corrections by customers.
Adding to the complexity, the company’s manufacturing facility in Pashamylaram, Hyderabad, recently received five observations from the US Food and Drug Administration (USFDA) in August 2026. While none of these observations involved data integrity issues, regulatory scrutiny can sometimes lead to delays in product approvals or exports, which investors typically monitor closely as they can impact future growth plans.
Leadership and Strategic Shift
In May 2026, the company appointed Umang Vohra, the former CEO of Cipla, as Executive Chairman and Group CEO. Vohra has been tasked with managing a company that expanded quickly by acquiring assets like ZCL Chemicals, RA Chem Pharma, and Avra Laboratories, and integrating them with Suven Pharmaceuticals. The core challenge for the new management is to improve the efficiency of these integrated units and convert existing customer opportunities into stable business.
Despite the poor quarterly results, the management remains optimistic about the future. Vohra stated that the June quarter represented the lowest point for the company. He anticipates a sequential improvement in the second quarter and a return to year-on-year growth in the second half of the fiscal year. This outlook is supported by improving order visibility, including restocking orders for commercial molecules.
Risks to Monitor
Investors are keeping a close watch on several factors beyond the quarterly numbers. The company is navigating high market volatility and has seen recent changes in institutional shareholding. Furthermore, the company has elevated levels of promoter pledging, which can be a point of concern for governance and financial flexibility. The success of the turnaround will depend heavily on the management’s ability to clean up regulatory issues at the Pashamylaram facility, stop the cash burn at the NJ Bio subsidiary, and manage the cyclical nature of its chemical business.
The most important updates for investors to track in the coming months will be the progress on USFDA compliance remediation, the performance trajectory of the NJ Bio subsidiary, and whether the company meets its targets for revenue and profitability recovery in the second half of the fiscal year.